Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 22, Number 3—March 2016

Online Report

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis

Jennifer FurinComments to Author , Grania Brigden, Erica Lessem, Michael Rich, Laura Vaughan, and Sharonann Lynch
Author affiliations: Harvard Medical School, Boston, Massachusettes, USA (J. Furin); Médecins Sans Frontières Access Campaign, Geneva, Switzerland (G. Brigden, S. Lynch); Treatment Action Group, New York, NY, USA (E. Lessem); Brigham and Women’s Hospital, Boston (M. Rich); Partners In Health, Boston (M. Rich, L. Vaughan)

Main Article

Table 3

Alphabetical list of core organizations participating in DR-TB STAT

National TB program director Implementing partner Technical assistance provider Donor Advocacy group
Global Drug Facility
Clinton Foundation
Global Fund for AIDS, TB, and Malaria
Global Coalition of TB Activists

Management Sciences for Health/Systems for Improved Access to Pharmaceutical and Services
Global TB Community Advisory Board
Russian Federation
KNCV Tuberculosis Foundation
Stop TB Partnership
US Agency for International Development

South Africa
Médecins Sans Frontières
Society Working on Implementation to Fight TB Response Project

Moldovan Society Against Tuberculosis
Partners in Health
World Health Organization


Treatment Action Campaign

Treatment Action Group
*DR, drug-resistant; STAT, Scale-up Treatment Action Team; TB, tuberculosis.

Main Article